HUTCHMED Stock Climbs 5.9% as Asset Sale Inflates Profit 11-Fold

Edgen Stock

·Mar 06 2026, 02:46

Share to

Share to

Copy link

Key Takeaways

HUTCHMED reported contradictory 2025 results, with a sharp drop in revenue offset by a massive, one-time gain in profit from selling assets. Investors reacted positively to the headline profit number, pushing the stock higher, but the underlying operational weakness raises questions about future growth.

HUTCHMED's stock (00013.HK) climbed 5.89% to HKD22.3 on March 6 after the company released its 2025 annual results.
Total revenue for 2025 fell by 13% year-over-year to $549 million, indicating a slowdown in core business activities.
A one-time gain from disposing of non-core businesses drove net income up 11-fold to $457 million, masking the operational revenue decline.

Stock Climbs 5.9% Despite Weaker Revenue

Shares of HUTCHMED (00013.HK) advanced on March 6 after the biopharmaceutical company reported conflicting annual results. The stock opened 0.57% higher and peaked at HKD22.3, ultimately closing with a 5.89% gain for the session. The move was backed by significant trading activity, with a volume of 1.28 million shares valued at HKD28.07 million.

Asset Sale Drives 11-Fold Profit Increase to $457 Million

The market's positive reaction stemmed from the company's 2025 earnings report, released on March 5. While total revenue contracted 13% year-over-year to $549 million, net income surged 11 times to reach $457 million, delivering an earnings per share of $0.53. This bottom-line performance was driven entirely by a net gain on the disposal of non-core businesses. The one-off event obscures the decline in the company's operational revenue, posing questions for investors about the sustainability of its earnings growth.